TriangleNCT02545907 · OUTCOME
Time to Amyloidotic Organ Response Based on Reported Data.
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Within 6 months
What was measured
The time to amyloidotic organ response (as outlined above) will be assessed based on reported data. The number of months this takes will be reported.
Groups in this outcome
Dose Level 0- Safety Population
All patients allocated to dose level 0 that received at least one dose of Carfilzomib and with no protocol deviations with relevant impact on safety will be included in the safety analysis set.
Dose Level 1- Safety Population
All patients allocated to dose level 1 that received at least one dose of Carfilzomib and with no protocol deviations with relevant impact on safety will be included in the safety analysis set.
| Group | Source count |
|---|---|
| Dose Level 0- Safety Population | 3 |
| Dose Level 1- Safety Population | 7 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Dose Level 0- Safety Population | 0 | Not reported | Not reported | Not reported | Not reported |
| Dose Level 1- Safety Population | 0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 7
- units
- Participants
- description
- The time to amyloidotic organ response (as outlined above) will be assessed based on reported data. The number of months this takes will be reported.
- groups
- description
- All patients allocated to dose level 0 that received at least one dose of Carfilzomib and with no protocol deviations with relevant impact on safety will be included in the safety analysis set.
- id
- OG000
- title
- Dose Level 0- Safety Population
- description
- All patients allocated to dose level 1 that received at least one dose of Carfilzomib and with no protocol deviations with relevant impact on safety will be included in the safety analysis set.
- id
- OG001
- title
- Dose Level 1- Safety Population
- param Type
- COUNT_OF_PARTICIPANTS
- reporting Status
- POSTED
- time Frame
- Within 6 months
- title
- Time to Amyloidotic Organ Response Based on Reported Data.
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice